Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07454941) titled 'Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology Omics' on March 2.

Study Type: Observational [Patient Registry]

Primary Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Condition: Urothelial Carcinoma (UC) HER2 Diagnostic

Recruitment Status: Recruiting

Date of First Enrollment: March 2, 2026

Target Sample Size: 4000

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07454941

Published by HT Digital Content Services with permission from Health Daily Digest....